Trial Profile
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF ALEGLITAZAR MONOTHERAPY COMPARED WITH PLACEBO IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2D) WHO ARE DRUG-NAIVE TO ANTI-HYPERGLYCEMIC THERAPY
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Aug 2016
Price :
$35
*
At a glance
- Drugs Aleglitazar (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AleGlucose
- Sponsors Roche
- 23 Jan 2014 Status changed from discontinued to completed, according to ClinicalTrials.gov record.
- 10 Jul 2013 Status changed from recruiting to discontinued, according to a Roche media release.
- 23 May 2013 Planned end date changed from 1 Jul 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.